Moore TJ, Furberg CD, Mattison DR, Cohen MR. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014. Pharmacoepidemiol Drug Saf 2016;25:713-8. [Ref.ID 100396]

Moore TJ, Furberg CD. Electronic health data for postmarket surveillance: a vision not realized. Drug Saf 2015;38:601-10. [Ref.ID 99852]

Moore TJ, Furberg CD. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US Food and Drug Administration. The class of 2008. JAMA Intern Med 2014;174:90-5. [Ref.ID 96996]

Beasley R, Singh S, Loke YK, Enright P, Furberg CD. Call for worldside withdrawal of tiotropium Respimat mist inhaler. BMJ 2012;345:9. [Ref.ID 94133]

Madigan D, Sigelman DW, Mayer JW, Furberg CD, Avorn J. Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. Am Heart J 2012;164:186-93. [Ref.ID 92938]

Moore TJ, Furberg CD, Glenmullen J, Maltsberger JT, Singh S. Suicidal behavior and depression in smoking cessation treatments. PLoS One 2011;6:e27016. [Ref.ID 91685]

Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Can Med Assoc J 2011;183:1-8. [Ref.ID 90781]

Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011;342:d3215. [Ref.ID 90762]

Singh S, Furberg CD. Inhaled anticholinergics for chronic obstructive pulmonary disease. Arch Intern Med 2011;171:920-2. [Ref.ID 90625]

Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Shceiman J, Sperling LS, Tomaselli GF, American College of Cardiology Foundation Task Force on Expert Consensus Documents. ACCF/ACCG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 2010;56:2051-66. [Ref.ID 89235]

Stafford RS, Bartholomew LK, Cushman WC, Cutler JA, Davis BR, Dawson G, Einhorn PT, Furberg CD, Piller LB, Pressel SL, Whelton PK, for the ALLHAT Collaborative Research Group. Impact of the ALLHAT/JNC7 dissemination project of thiazide-type diuretic use. Arch Intern Med 2010;170:851-8. [Ref.ID 88578]

Boger-Megiddo I, Heckbert SR, Weiss NS, McKnight B, Furberg CD, Wiggins KL, Delaney JAC, Siscovick DS, Larson EB, Lemaitre RN, Smith NL, Rice KM, Glazer NL, Psaty BM. Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. BMJ 2010;340:303. [Ref.ID 87762]

Singh S, Loke YK, Furberg CD. Risk of major adverse cardiovascular events with inhaled anticholinergics in patients with chronic obstructive pulmonary disease. In reply. JAMA 2009;301:1225-6. [Ref.ID 85517]

Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Can Med Assoc J 2009;180:32-9. [Ref.ID 85099]

Singh S, Furberg CD, Loke YK. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360:186. [Ref.ID 85073]

DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, López OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD, for the Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia. A randomized controlled trial. JAMA 2008;300:2253-62. [Ref.ID 84565]

Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300:1439-50. [Ref.ID 84028]

Sniderman AD, Furberg CD. Age as a modifiable risk factor for cardiovascular disease. Lancet 2008;371:1547-9. [Ref.ID 82803]

Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007;167:1752-9. [Ref.ID 81063]

Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone. A meta-analysis. JAMA 2007;298:1189-95. [Ref.ID 81023]